Metastatic Hepatocellular Carcinoma (HCC) - Pipeline Review, H2 2016

Published: Aug, 2016 | Pages: 131 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Metastatic Hepatocellular Carcinoma (HCC) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Metastatic Hepatocellular Carcinoma (HCC) - Pipeline Review, H2 2016', provides an overview of the Metastatic Hepatocellular Carcinoma (HCC) pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Metastatic Hepatocellular Carcinoma (HCC), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Metastatic Hepatocellular Carcinoma (HCC) and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Metastatic Hepatocellular Carcinoma (HCC)
- The report reviews pipeline therapeutics for Metastatic Hepatocellular Carcinoma (HCC) by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Metastatic Hepatocellular Carcinoma (HCC) therapeutics and enlists all their major and minor projects
- The report assesses Metastatic Hepatocellular Carcinoma (HCC) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Metastatic Hepatocellular Carcinoma (HCC)

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Metastatic Hepatocellular Carcinoma (HCC)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Metastatic Hepatocellular Carcinoma (HCC) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table Of Content

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Metastatic Hepatocellular Carcinoma (HCC) Overview 9
Therapeutics Development 10
Pipeline Products for Metastatic Hepatocellular Carcinoma (HCC) - Overview 10
Pipeline Products for Metastatic Hepatocellular Carcinoma (HCC) - Comparative Analysis 11
Metastatic Hepatocellular Carcinoma (HCC) - Therapeutics under Development by Companies 12
Metastatic Hepatocellular Carcinoma (HCC) - Therapeutics under Investigation by Universities/Institutes 14
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline Products Glance 15
Clinical Stage Products 15
Early Stage Products 16
Metastatic Hepatocellular Carcinoma (HCC) - Products under Development by Companies 17
Metastatic Hepatocellular Carcinoma (HCC) - Products under Investigation by Universities/Institutes 18
Metastatic Hepatocellular Carcinoma (HCC) - Companies Involved in Therapeutics Development 19
Acceleron Pharma, Inc. 19
AstraZeneca Plc 20
AVEO Pharmaceuticals, Inc. 21
Celgene Corporation 22
Eisai Co., Ltd. 23
Eli Lilly and Company 24
F. Hoffmann-La Roche Ltd. 25
HanAll Biopharma Co., Ltd. 26
Johnson & Johnson 27
Millennium Pharmaceuticals Inc 28
Mirna Therapeutics, Inc. 29
Molecular Partners AG 30
MolMed S.p.A. 31
Novartis AG 32
OncoMed Pharmaceuticals, Inc. 33
Pfizer Inc. 34
PharmAbcine, Inc. 35
Verlyx Pharma Inc. 36
Metastatic Hepatocellular Carcinoma (HCC) - Therapeutics Assessment 37
Assessment by Monotherapy Products 37
Assessment by Target 38
Assessment by Mechanism of Action 41
Assessment by Route of Administration 44
Assessment by Molecule Type 46
Drug Profiles 48
AV-203 - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
AZD-9150 - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
CC-122 - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
Cellular Immunotherapy for Metastatic Hepatocellular Carcinoma - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
codrituzumab - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
crizotinib - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
dalantercept - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
emibetuzumab - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
erdafitinib - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
golvatinib tartrate - Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
HL-143 - Drug Profile 75
Product Description 75
Mechanism Of Action 75
R&D Progress 75
ipafricept - Drug Profile 76
Product Description 76
Mechanism Of Action 76
R&D Progress 76
LY-3039478 - Drug Profile 80
Product Description 80
Mechanism Of Action 80
R&D Progress 80
LY-3127804 - Drug Profile 81
Product Description 81
Mechanism Of Action 81
R&D Progress 81
MP-0250 - Drug Profile 82
Product Description 82
Mechanism Of Action 82
R&D Progress 82
MRX-34 - Drug Profile 83
Product Description 83
Mechanism Of Action 83
R&D Progress 83
NGR-hTNF - Drug Profile 89
Product Description 89
Mechanism Of Action 89
R&D Progress 89
OSU-2S - Drug Profile 95
Product Description 95
Mechanism Of Action 95
R&D Progress 95
palbociclib - Drug Profile 96
Product Description 96
Mechanism Of Action 96
R&D Progress 96
pasireotide - Drug Profile 106
Product Description 106
Mechanism Of Action 106
R&D Progress 106
pentamidine isethionate - Drug Profile 110
Product Description 110
Mechanism Of Action 110
R&D Progress 110
PF-04518600 - Drug Profile 112
Product Description 112
Mechanism Of Action 112
R&D Progress 112
PTX-9908 - Drug Profile 113
Product Description 113
Mechanism Of Action 113
R&D Progress 113
sapanisertib - Drug Profile 114
Product Description 114
Mechanism Of Action 114
R&D Progress 114
sonidegib phosphate - Drug Profile 117
Product Description 117
Mechanism Of Action 117
R&D Progress 117
temsirolimus - Drug Profile 122
Product Description 122
Mechanism Of Action 122
R&D Progress 122
TTAC-0001 - Drug Profile 124
Product Description 124
Mechanism Of Action 124
R&D Progress 124
utomilumab - Drug Profile 125
Product Description 125
Mechanism Of Action 125
R&D Progress 125
Metastatic Hepatocellular Carcinoma (HCC) - Dormant Projects 127
Metastatic Hepatocellular Carcinoma (HCC) - Discontinued Products 128
Metastatic Hepatocellular Carcinoma (HCC) - Product Development Milestones 129
Featured News & Press Releases 129
Jul 30, 2013: Mirna Therapeutics Announces Important Expansion of microRNA Patent Portfolio 129
May 13, 2013: Marina Biotech's Licensee Mirna Therapeutics Initiates Phase I Clinical Trial Of Anticancer Drug MRX34 129
Appendix 130
Methodology 130
Coverage 130
Secondary Research 130
Primary Research 130
Expert Panel Validation 130
Contact Us 130
Disclaimer 131

List Of Tables

Number of Products under Development for Metastatic Hepatocellular Carcinoma (HCC), H2 2016 10
Number of Products under Development for Metastatic Hepatocellular Carcinoma (HCC) - Comparative Analysis, H2 2016 11
Number of Products under Development by Companies, H2 2016 13
Number of Products under Investigation by Universities/Institutes, H2 2016 14
Comparative Analysis by Clinical Stage Development, H2 2016 15
Comparative Analysis by Early Stage Development, H2 2016 16
Products under Development by Companies, H2 2016 17
Products under Investigation by Universities/Institutes, H2 2016 18
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Acceleron Pharma, Inc., H2 2016 19
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by AstraZeneca Plc, H2 2016 20
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by AVEO Pharmaceuticals, Inc., H2 2016 21
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Celgene Corporation, H2 2016 22
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Eisai Co., Ltd., H2 2016 23
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Eli Lilly and Company, H2 2016 24
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 25
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by HanAll Biopharma Co., Ltd., H2 2016 26
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Johnson & Johnson, H2 2016 27
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Millennium Pharmaceuticals Inc, H2 2016 28
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Mirna Therapeutics, Inc., H2 2016 29
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Molecular Partners AG, H2 2016 30
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by MolMed S.p.A., H2 2016 31
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Novartis AG, H2 2016 32
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by OncoMed Pharmaceuticals, Inc., H2 2016 33
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Pfizer Inc., H2 2016 34
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by PharmAbcine, Inc., H2 2016 35
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Verlyx Pharma Inc., H2 2016 36
Assessment by Monotherapy Products, H2 2016 37
Number of Products by Stage and Target, H2 2016 39
Number of Products by Stage and Mechanism of Action, H2 2016 42
Number of Products by Stage and Route of Administration, H2 2016 45
Number of Products by Stage and Molecule Type, H2 2016 47
Metastatic Hepatocellular Carcinoma (HCC) - Dormant Projects, H2 2016 127
Metastatic Hepatocellular Carcinoma (HCC) - Discontinued Products, H2 2016 128